EX-99.12uhs-ex99_1.htmEX-99.1 EX-99.1
Exhibit 99.1
FOR IMMEDIATE RELEASE
February 26, 2025
CONTACT:
Steve Filton
Chief Financial Officer
610-768-3300
UNIVERSAL HEALTH SERVICES, INC.
ANNOUNCES 2024 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
AND 2025 OPERATING RESULTS FORECAST
Consolidated Results of Operations, As Reported and As Adjusted – Three-month periods ended December 31, 2024 and 2023:
KING OF PRUSSIA, PA – Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $332.4 million, or $4.96 per diluted share, during the fourth quarter of 2024, as compared to $216.4 million, or $3.16 per diluted share, during the fourth quarter of 2023. Net revenues increased by 11.1% to $4.114 billion during the fourth quarter of 2024, as compared to $3.704 billion during the fourth quarter of 2023.
As reflected on the Schedule of Non-GAAP Supplemental Information (“Supplemental Schedule”), our adjusted net income attributable to UHS during the fourth quarter of 2024 was $329.9 million, or $4.92 per diluted share, as compared to $214.9 million, or $3.13 per diluted share, during the fourth quarter of 2023.
As reflected on the Supplemental Schedule, included in our reported results during the fourth quarter of 2024 were: (i) an unrealized after-tax gain of $2.1 million, or $.03 per diluted share ($2.7 million pre-tax), resulting from an increase in the market value of certain equity securities (included in “Other (income) expense, net”), and; (ii) a favorable net after-tax impact of $407,000, or $.01 per diluted share, resulting from the net tax benefit recorded pursuant to “ASU 2016-09”, Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting.
Included in our reported and adjusted net income attributable to UHS during the fourth quarter of 2023, were net incremental reimbursements (net of related provider taxes) of approximately $17.8 million, or $.20 per diluted share, recorded in connection with the Mississippi Hospital Access Program covering the period of July 1, 2023, through December 31, 2023. In addition, as reflected on the Supplemental Schedule, included in our reported results during the fourth quarter of 2023, was an unrealized after-tax gain of $1.5 million, or $.03 per diluted share ($1.9 million pre-tax), resulting from an increase in the market value of certain equity securities.
As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”, NCI is net income attributable to noncontrolling interests), was $620.2 million during the fourth quarter of 2024, as compared to $476.9 million during the fourth quarter of 2023. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $614.6 million during the fourth quarter of 2024, as compared to $473.4 million during the fourth quarter of 2023.
Consolidated Results of Operations, As Reported and As Adjusted – Twelve-month periods ended December 31, 2024 and 2023:
Reported net income attributable to UHS was $1.142 billion, or $16.82 per diluted share, during the full year 2024, as compared to $717.8 million, or $10.23 per diluted share, during 2023. Net revenues increased by 10.8% to $15.828 billion during the full year of 2024, as compared to $14.282 billion during 2023.
As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the twelve-month period ended December 31, 2024, was $1.128 billion, or $16.61 per diluted share, as compared to $739.4 million, or $10.54 per diluted share, during the twelve-month period ended December 31, 2023.
As reflected on the Supplemental Schedule, included in our reported results during the full year of 2024 were: (i) an unrealized after-tax loss of $2.0 million, or $.03 per diluted share ($2.6 million pre-tax), resulting from a decrease in the market value of certain equity securities (included in “Other (income) expense, net”), and; (ii) a favorable net after-tax impact of $15.9 million, or $.24 per diluted share, resulting from the above-mentioned net tax benefit recorded in connection with ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m).
As reflected on the Supplemental Schedule, included in our reported results during 2023 was an unrealized after-tax loss of $21.6 million, or $.31 per diluted share ($28.2 million pre-tax) resulting from a decrease in the market value of certain equity securities.
As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization (“EBITDA net of NCI”), was $2.248 billion during the full year of 2024, as compared to $1.714 billion during the full year of 2023. Our adjusted earnings before interest, taxes, depreciation & amortization (“Adjusted EBITDA net of NCI”), which excludes the impact of other (income) expense, net, was $2.246 billion during the full year of 2024, as compared to $1.742 billion during the full year of 2023.
Acute Care Services – Three and twelve-month periods ended December 31, 2024 and 2023:
During the fourth quarter of 2024, at our acute care hospitals owned during both periods (“same facility basis”), adjusted admissions (adjusted for outpatient activity) increased by 2.2% while adjusted patient days increased by 0.1%, as compared to the fourth quarter of 2023. At these facilities, during the fourth quarter of 2024, net revenue per adjusted admission increased by 5.3% while net revenue per adjusted patient day increased by 7.5%, as compared to the fourth quarter of 2023. Net revenues generated from our acute care services, on a same facility basis, increased by 8.7% during the fourth quarter of 2024, as compared to the fourth quarter of 2023.
During the twelve-month period ended December 31, 2024, at our acute care hospitals on a same facility basis, adjusted admissions increased by 2.9% while adjusted patient days increased by 1.8%, as compared to the year ended December 31, 2023. At these facilities, during the full year of 2024, net revenue per adjusted admission increased by 5.1% while net revenue per adjusted patient day increased by 6.3%, as compared to 2023. Net revenues generated from our acute care services, on a same facility basis, increased by 8.5% during the full year of 2024, as compared to 2023.
Behavioral Health Care Services – Three and twelve-month periods ended December 31, 2024 and 2023:
During the fourth quarter of 2024, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 2.0% while adjusted patient days increased by 1.6%, as compared to the fourth quarter of 2023. At these facilities, during the fourth quarter of 2024, net revenue per adjusted admission increased by 8.7% and net revenue per adjusted patient day increased by 9.1%, as compared to the fourth quarter of 2023. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 11.1% during the fourth quarter of 2024, as compared to the fourth quarter of 2023.
During the twelve-month period ended December 31, 2024, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 0.7% while adjusted patient days increased by 1.7%, as compared to the comparable period of 2023. At these facilities, during the full year of 2024, net revenue per adjusted admission increased by 9.8% and net revenue per adjusted patient day increased by 8.8%, as compared to 2023. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 10.7% during 2024, as compared to 2023.
Net Cash Provided by Operating Activities and Liquidity:
Net Cash Provided by Operating Activities:
During the twelve-month period ended December 31, 2024, our net cash provided by operating activities was $2.067 billion as compared to $1.268 billion during the full year of 2023. The $799 million net increase in our net cash provided by operating activities consisted of: (i) a favorable change of $472 million resulting from an increase in net income plus/minus depreciation and amortization expense, stock-based compensation expense, gains on sales of assets and businesses and costs related to the extinguishment of debt; (ii) a favorable change of $250 million in accounts receivable due, in part, to a decrease in our days sales outstanding to 50
days at December 31, 2024, as compared to 57 days at December 31, 2023; (iii) a favorable change of $94 million in other working capital accounts due primarily to the timing of disbursements for certain accrued liabilities; (iv) an unfavorable change of $61 million in other assets and deferred charges; (v) a favorable change of $56 million in accrued and deferred income taxes, and; (vi) $12 million of other combined net unfavorable changes.
Liquidity:
As of December 31, 2024, we had $1.17 billion of aggregate available borrowing capacity pursuant to our $1.3 billion revolving credit facility, net of outstanding borrowings and letters of credit.
Stock Repurchase Program:
In connection with our stock repurchase program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.
Pursuant to this program, during the fourth quarter of 2024, we have repurchased approximately 1.25 million shares at an aggregate cost of approximately $249.6 million (average price of approximately $199 per share). During the full year of 2024, we have repurchased approximately 2.98 million shares at an aggregate cost of approximately $598.5 million (average price of approximately $201 per share).
As of December 31, 2024, we had an aggregate available repurchase authorization of approximately $824.4 million pursuant to our stock repurchase program.
2025 Operating Results Forecast:
Reflected below is our 2025 forecasted range for consolidated net revenues, earnings before interest, taxes, depreciation & amortization, and the impacts of other income/expense and net income attributable to noncontrolling interests (“Adjusted EBITDA net of NCI”), net income attributable to UHS per diluted share (“EPS-diluted”) and capital expenditures.
Our 2025 forecasted range of net income attributable to UHS, and EPS-diluted, exclude certain items as described below because we do not believe we can forecast those items with sufficient accuracy. Adjusted EBITDA net of NCI, is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of our operating performance. Please see the Supplemental Non-GAAP Disclosures - 2025 Operating Results Forecast schedule as included herein for additional information and a reconciliation of our 2025 forecasted range of net income attributable to UHS to our 2025 forecasted range of Adjusted EBITDA net of NCI.
For the Year Ended
December 31, 2025
Low
High
G1Net revenues
$17.020 billion
$17.364 billion
G2Adjusted EBITDA net of NCI
$2.357 billion
$2.484 billion
G3EPS-diluted
$18.45 per share
$19.95 per share
Capital expenditures
$850 million
$1.000 billion
Our 2025 operating results forecast contains a number of assumptions including, but not limited to, the following:
•
The 2025 forecasted amounts exclude the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as changes in the market value of shares of certain equity securities, the impact of ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m), and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, other amounts that may be reflected in the current or prior year financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions. It is also subject to certain
conditions including those as set forth below in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.
•
Our net revenues are estimated to be approximately $17.020 billion to $17.364 billion representing an increase of 7.5% to 9.7% over our 2024 net revenues of $15.828 billion.
•
Our Adjusted EBITDA net of NCI is estimated to be approximately $2.357 billion to $2.484 billion representing an increase of 4.9% to 10.6% over our 2024 Adjusted EBITDA net of NCI of $2.246 billion.
•
Our EPS-diluted range is estimated to be $18.45 per diluted share to $19.95 per diluted share, representing an increase of 11.1% to 20.1% over our adjusted net income attributable to UHS of $16.61 per diluted share for the year ended December 31, 2024, as calculated on the attached Supplemental Schedule.
Conference call information:
We will hold a conference call for investors and analysts at 10:00 a.m. eastern time on February 27, 2025. A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.
General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:
One of the nation’s largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. (the “Company”) has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2024 were $15.828 billion. UHS ranked #299 on the Fortune 500; and #399 on Forbes’ list of America’s Largest Public Companies. In 2025, UHS was again recognized as one of the World’s Most Admired Companies by Fortune.
Our operating philosophy is as effective today as it was upon the Company’s founding in 1979, enabling us to provide compassionate care to our patients and their loved ones. Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.
Headquartered in King of Prussia, PA, UHS has approximately 99,000 employees and, through its subsidiaries, operates 28 inpatient acute care hospitals, 331 inpatient behavioral health facilities, 60 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information visit www.uhs.com.
This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 1A-Risk Factors, and Item 7-Forward-Looking Statements and Risk Factors, in our Form 10-K for the year ended December 31, 2024), may cause the results to differ materially from those anticipated in the forward-looking statements. These statements are subject to risks and uncertainties and therefore actual results may differ materially. Readers should not place undue reliance on such forward-looking statements which reflect management’s view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:
•
A significant portion of our revenues are derived from federal and state government programs including the Medicare and Medicaid programs. Payments from these programs are subject to statutory and regulatory changes, administrative rulings, interpretations and determinations, requirements for utilization review, and federal and state funding restrictions. Changes to these programs, if adopted, could materially affect program payments which could materially impact our results of operations. In addition, we receive substantial reimbursement from multiple states in connection with various supplemental Medicaid payment programs. Failure to renew these programs beyond their scheduled termination dates, failure of the public hospitals to provide the necessary Inter-Governmental Transfers for the states’ share of the Medicaid disproportionate share hospital programs, failure of our hospitals that currently receive supplemental Medicaid revenues to qualify for future funds under these programs, the adoption of certain proposed reductions of federal funding for Medicaid, or reductions in other reimbursements, could cause our actual results of operations for the year ended December 31, 2025 to differ materially from our 2025 operating results forecast.
•
The increase in interest rates during the past few years has increased our interest expense significantly thereby reducing our free cash flow. As such, although interest rates have moderated more recently, the effects of increased borrowing rates have adversely impacted our results of operations, financial condition and cash flows. We cannot predict future changes to interest rates, however, significant increases in our borrowing rates could have a material unfavorable impact on our future results of operations and our ability to access the capital markets on favorable terms;
•
The outcome of known and unknown litigation, liabilities and other claims asserted against us and/or our subsidiaries, including, but not limited to, the matters related to Cumberland Hospital for Children and Adolescents, located in New Kent, Virginia, as previously disclosed on Form 8-K on September 30, 2024, Form 10-Q for the quarterly period ended September 30, 2024 and Form 10-K for the year ended December 31, 2024; and the matter related to the Pavilion Behavioral Health System, located in Champaign, Illinois, as previously disclosed on Forms 8-K on April 1, 2024, September 30, 2024 and October 11, 2024, Forms 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and Form 10-K for the year ended December 31, 2024.
Although we can make no assurances regarding the ultimate outcome of these matters, or what damages will ultimately be awarded, the final resolution of these matters could have a material adverse effect on the Company.
We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures (“GAAP” is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities, the impact of ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m), and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods.
To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-K for the year ended December 31, 2024. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly
titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.
(more)
Universal Health Services, Inc.
Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)
Three months
Twelve months
ended December 31,
ended December 31,
2024
2023
2024
2023
Net revenues
$
4,113,722
3,703,546
$
15,827,935
14,281,976
Operating charges:
Salaries, wages and benefits
1,907,383
1,799,008
7,518,687
7,107,484
Other operating expenses
1,142,901
998,732
4,308,384
3,757,216
Supplies expense
405,900
393,878
1,587,786
1,532,828
Depreciation and amortization
146,781
145,481
584,831
568,041
Lease and rental expense
38,268
35,251
146,433
141,026
3,641,233
3,372,350
14,146,121
13,106,595
Income from operations
472,489
331,196
1,681,814
1,175,381
Interest expense, net
39,724
53,589
186,109
206,674
Other (income) expense, net
(5,546
)
(3,516
)
(2,231
)
28,281
Income before income taxes
438,311
281,123
1,497,936
940,426
Provision for income taxes
101,264
61,501
334,827
221,119
Net income
337,047
219,622
1,163,109
719,307
Less: Net income (loss) attributable to noncontrolling interests ("NCI")
4,650
3,244
21,012
1,512
Net income attributable to UHS
$
332,397
$
216,378
$
1,142,097
$
717,795
Basic earnings per share attributable to UHS (a)
$
5.07
$
3.19
$
17.16
$
10.35
Diluted earnings per share attributable to UHS (a)
$
4.96
$
3.16
$
16.82
$
10.23
Universal Health Services, Inc.
Footnotes to Consolidated Statements of Income
(in thousands, except per share amounts)
(unaudited)
Three months
Twelve months
ended December 31,
ended December 31,
2024
2023
2024
2023
(a) Earnings per share calculation:
Basic and diluted:
Net income attributable to UHS
$
332,397
$
216,378
$
1,142,097
$
717,795
Less: Net income attributable to unvested restricted share grants
0
(66
)
(50
)
(308
)
Net income attributable to UHS - basic and diluted
$
332,397
$
216,312
$
1,142,047
$
717,487
Weighted average number of common shares - basic
65,597
67,809
66,554
69,321
Basic earnings per share attributable to UHS:
$
5.07
$
3.19
$
17.16
$
10.35
Weighted average number of common shares
65,597
67,809
66,554
69,321
Add: Other share equivalents
1,477
741
1,342
804
Weighted average number of common shares and equiv. - diluted
67,074
68,550
67,896
70,125
Diluted earnings per share attributable to UHS:
$
4.96
$
3.16
$
16.82
$
10.23
Universal Health Services, Inc.
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Three Months ended December 31, 2024 and 2023
(in thousands, except per share amounts)
(unaudited)
Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")
Three months ended
% Net
Three months ended
% Net
December 31, 2024
revenues
December 31, 2023
revenues
Net income attributable to UHS
$
332,397
$
216,378
Depreciation and amortization
146,781
145,481
Interest expense, net
39,724
53,589
Provision for income taxes
101,264
61,501
EBITDA net of NCI
$
620,166
15.1
%
$
476,949
12.9
%
Other (income) expense, net
(5,546
)
(3,516
)
Adjusted EBITDA net of NCI
$
614,620
14.9
%
$
473,433
12.8
%
Net revenues
$
4,113,722
$
3,703,546
Calculation of Adjusted Net Income Attributable to UHS
Three months ended
Three months ended
December 31, 2024
December 31, 2023
Per
Per
Amount
Diluted Share
Amount
Diluted Share
Net income attributable to UHS
$
332,397
$
4.96
$
216,378
$
3.16
Plus/minus after-tax adjustments:
Unrealized gain on equity securities
(2,053
)
(0.03
)
(1,470
)
(0.03
)
Impact of ASU 2016-09, net
(407
)
(0.01
)
-
-
Subtotal adjustments
(2,460
)
(0.04
)
(1,470
)
(0.03
)
Adjusted net income attributable to UHS
$
329,937
$
4.92
$
214,908
$
3.13
Universal Health Services, Inc.
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule")
For the Twelve Months ended December 31, 2024 and 2023
(in thousands, except per share amounts)
(unaudited)
Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI")
Twelve months ended
% Net
Twelve months ended
% Net
December 31, 2024
revenues
December 31, 2023
revenues
Net income attributable to UHS
$
1,142,097
$
717,795
Depreciation and amortization
584,831
568,041
Interest expense, net
186,109
206,674
Provision for income taxes
334,827
221,119
EBITDA net of NCI
$
2,247,864
14.2
%
$
1,713,629
12.0
%
Other (income) expense, net
(2,231
)
28,281
Adjusted EBITDA net of NCI
$
2,245,633
14.2
%
$
1,741,910
12.2
%
Net revenues
$
15,827,935
$
14,281,976
Calculation of Adjusted Net Income Attributable to UHS
Twelve months ended
Twelve months ended
December 31, 2024
December 31, 2023
Per
Per
Amount
Diluted Share
Amount
Diluted Share
Net income attributable to UHS
$
1,142,097
$
16.82
$
717,795
$
10.23
Plus/minus after-tax adjustments:
Unrealized loss on equity securities
$
1,985
0.03
21,570
0.31
Impact of ASU 2016-09, net
(15,947
)
(0.24
)
-
-
Subtotal adjustments
(13,962
)
(0.21
)
21,570
0.31
Adjusted net income attributable to UHS
$
1,128,135
$
16.61
$
739,365
$
10.54
Universal Health Services, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
December 31,
December 31,
2024
2023
Assets
Current assets:
Cash and cash equivalents
$
125,983
$
119,439
Accounts receivable, net
2,177,751
2,238,265
Supplies
220,940
216,988
Other current assets
291,614
236,658
Total current assets
2,816,288
2,811,350
Property and equipment
12,643,283
11,777,047
Less: accumulated depreciation
(6,071,058
)
(5,652,518
)
6,572,225
6,124,529
Other assets:
Goodwill
3,932,879
3,932,407
Deferred income taxes
118,449
85,626
Right of use assets-operating leases
418,719
433,962
Deferred charges
9,404
6,974
Other
601,785
572,754
Total Assets
$
14,469,749
$
13,967,602
Liabilities and Stockholders' Equity
Current liabilities:
Current maturities of long-term debt
$
40,059
$
126,686
Accounts payable and other liabilities
2,081,479
1,813,015
Operating lease liabilities
74,649
71,600
Federal and state taxes
14,219
2,046
Total current liabilities
2,210,406
2,013,347
Other noncurrent liabilities
655,806
584,007
Operating lease liabilities noncurrent
376,239
382,559
Long-term debt
4,464,482
4,785,783
Redeemable noncontrolling interest
13,293
5,191
UHS common stockholders' equity
6,666,207
6,149,001
Noncontrolling interest
83,316
47,714
Total equity
6,749,523
6,196,715
Total Liabilities and Stockholders' Equity
$
14,469,749
$
13,967,602
Universal Health Services, Inc.
Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
Twelve months
ended December 31,
2024
2023
Cash Flows from Operating Activities:
Net income
$
1,163,109
$
719,307
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation & amortization
584,831
568,041
Gains on sales of assets and businesses
(9,920
)
(6,250
)
Stock-based compensation expense
99,349
87,720
Costs related to extinguishment of debt
3,158
0
Changes in assets & liabilities, net of effects from acquisitions and dispositions:
Accounts receivable
67,355
(182,444
)
Accrued interest
12,814
1,193
Accrued and deferred income taxes
12,651
(43,450
)
Other working capital accounts
61,897
(32,321
)
Deferred grant revenue
0
2,978
Other assets and deferred charges
(12,163
)
48,517
Other
21,811
39,133
Accrued insurance expense, net of commercial premiums paid
254,394
183,462
Payments made in settlement of self-insurance claims
(192,185
)
(118,089
)
Net cash provided by operating activities
2,067,101
1,267,797
Cash Flows from Investing Activities:
Property and equipment additions
(943,810
)
(743,055
)
Acquisition of businesses and property
(18,998
)
(3,728
)
Inflows (outflows) from foreign exchange contracts that hedge our net U.K. investment
12,860
(40,695
)
Proceeds received from sales of assets and businesses
38,563
24,187
Decrease in capital reserves of commercial insurance subsidiary
276
16
Net cash used in investing activities
(911,109
)
(763,275
)
Cash Flows from Financing Activities:
Repayments of long-term debt
(2,640,001
)
(85,480
)
Additional borrowings
2,210,248
185,100
Financing costs
(12,566
)
(308
)
Repurchase of common shares
(670,754
)
(547,363
)
Dividends paid
(53,346
)
(55,480
)
Issuance of common stock
15,070
13,654
Profit distributions to noncontrolling interests
(6,508
)
(6,830
)
Sale of ownership interests to minority members
12,980
2,762
Net cash used in financing activities
(1,144,877
)
(493,945
)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
(833
)
3,056
Increase in cash, cash equivalents and restricted cash
10,282
13,633
Cash, cash equivalents and restricted cash, beginning of period
214,470
200,837
Cash, cash equivalents and restricted cash, end of period
$
224,752
$
214,470
Supplemental Disclosures of Cash Flow Information:
Interest paid
$
168,274
$
200,446
Income taxes paid, net of refunds
$
325,430
$
257,896
Noncash purchases of property and equipment
$
118,109
$
66,899
Universal Health Services, Inc.
Supplemental Statistical Information
(unaudited)
% Change
% Change
Same Facility:
Three Months ended
Year ended
12/31/2024
12/31/2024
Acute Care Services
Revenues
8.7%
8.5%
Adjusted Admissions
2.2%
2.9%
Adjusted Patient Days
0.1%
1.8%
Revenue Per Adjusted Admission
5.3%
5.1%
Revenue Per Adjusted Patient Day
7.5%
6.3%
Behavioral Health Care Services
Revenues
11.1%
10.7%
Adjusted Admissions
2.0%
0.7%
Adjusted Patient Days
1.6%
1.7%
Revenue Per Adjusted Admission
8.7%
9.8%
Revenue Per Adjusted Patient Day
9.1%
8.8%
UHS Consolidated
Fourth quarter ended
Year ended
12/31/2024
12/31/2023
12/31/2024
12/31/2023
Revenues
$4,113,722
$3,703,546
$15,827,935
$14,281,976
EBITDA net of NCI
$620,166
$476,949
$2,247,864
$1,713,629
EBITDA Margin net of NCI
15.1%
12.9%
14.2%
12.0%
Adjusted EBITDA net of NCI
$614,620
$473,433
$2,245,633
$1,741,910
Adjusted EBITDA Margin net of NCI
14.9%
12.8%
14.2%
12.2%
Cash Flow From Operations
$658,437
$452,431
$2,067,101
$1,267,797
Capital Expenditures
$245,945
$206,390
$943,810
$743,055
Days Sales Outstanding
50
57
Debt
$4,504,541
$4,912,469
UHS' Shareholders Equity
$6,666,207
$6,149,001
Debt / Total Capitalization
40.3%
44.4%
Debt / EBITDA net of NCI (1)
2.00
2.87
Debt / Adjusted EBITDA net of NCI (1)
2.01
2.82
Debt / Cash From Operations (1)
2.18
3.87
(1) Latest 4 quarters.
Universal Health Services, Inc.
Acute Care Hospital Services
For the Three and Twelve Months ended
December 31, 2024 and 2023
(in thousands)
(unaudited)
Same Facility Basis - Acute Care Hospital Services
Three months ended
Three months ended
Twelve months ended
Twelve months ended
December 31, 2024
December 31, 2023
December 31, 2024
December 31, 2023
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Net revenues
$
2,210,767
100.0
%
$
2,034,152
100.0
%
$
8,565,845
100.0
%
$
7,892,167
100.0
%
Operating charges:
Salaries, wages and benefits
893,101
40.4
%
870,680
42.8
%
3,502,645
40.9
%
3,387,843
42.9
%
Other operating expenses
623,513
28.2
%
559,985
27.5
%
2,378,512
27.8
%
2,164,069
27.4
%
Supplies expense
347,034
15.7
%
338,815
16.7
%
1,358,636
15.9
%
1,315,527
16.7
%
Depreciation and amortization
86,845
3.9
%
93,421
4.6
%
364,907
4.3
%
367,067
4.7
%
Lease and rental expense
26,422
1.2
%
23,970
1.2
%
98,730
1.2
%
96,429
1.2
%
Subtotal-operating expenses
1,976,915
89.4
%
1,886,871
92.8
%
7,703,430
89.9
%
7,330,935
92.9
%
Income from operations
233,852
10.6
%
147,281
7.2
%
862,415
10.1
%
561,232
7.1
%
Interest expense, net
2,976
0.1
%
(643
)
(0.0
)%
6,339
0.1
%
(2,501
)
(0.0
)%
Other (income) expense, net
(775
)
(0.0
)%
1,277
0.1
%
(2,123
)
(0.0
)%
7,000
0.1
%
Income before income taxes
$
231,651
10.5
%
$
146,647
7.2
%
$
858,199
10.0
%
$
556,733
7.1
%
All Acute Care Hospital Services
Three months ended
Three months ended
Twelve months ended
Twelve months ended
December 31, 2024
December 31, 2023
December 31, 2024
December 31, 2023
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Net revenues
$
2,318,320
100.0
%
$
2,087,503
100.0
%
$
8,922,327
100.0
%
$
8,081,402
100.0
%
Operating charges:
Salaries, wages and benefits
899,241
38.8
%
871,182
41.7
%
3,511,359
39.4
%
3,406,060
42.1
%
Other operating expenses
734,189
31.7
%
615,810
29.5
%
2,743,420
30.7
%
2,347,560
29.0
%
Supplies expense
348,551
15.0
%
338,732
16.2
%
1,360,011
15.2
%
1,317,917
16.3
%
Depreciation and amortization
89,048
3.8
%
93,479
4.5
%
368,096
4.1
%
367,644
4.5
%
Lease and rental expense
26,422
1.1
%
23,960
1.1
%
99,060
1.1
%
96,589
1.2
%
Subtotal-operating expenses
2,097,451
90.5
%
1,943,163
93.1
%
8,081,946
90.6
%
7,535,770
93.2
%
Income from operations
220,869
9.5
%
144,340
6.9
%
840,381
9.4
%
545,632
6.8
%
Interest expense, net
2,976
0.1
%
(643
)
(0.0
)%
6,339
0.1
%
(2,501
)
(0.0
)%
Other (income) expense, net
(951
)
(0.0
)%
867
0.0
%
(1,305
)
(0.0
)%
7,788
0.1
%
Income before income taxes
$
218,844
9.4
%
$
144,116
6.9
%
$
835,347
9.4
%
$
540,345
6.7
%
We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods.
Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2024.
The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months.
Universal Health Services, Inc.
Behavioral Health Care Services
For the Three and Twelve Months ended
December 31, 2024 and 2023
(in thousands)
(unaudited)
Same Facility - Behavioral Health Care Services
Three months ended
Three months ended
Twelve months ended
Twelve months ended
December 31, 2024
December 31, 2023
December 31, 2024
December 31, 2023
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Net revenues
$
1,727,857
100.0
%
$
1,555,700
100.0
%
$
6,700,469
100.0
%
$
6,050,491
100.0
%
Operating charges:
Salaries, wages and benefits
911,047
52.7
%
851,507
54.7
%
3,590,985
53.6
%
3,346,357
55.3
%
Other operating expenses
328,339
19.0
%
299,035
19.2
%
1,262,446
18.8
%
1,168,806
19.3
%
Supplies expense
58,201
3.4
%
55,509
3.6
%
229,795
3.4
%
216,880
3.6
%
Depreciation and amortization
55,050
3.2
%
48,879
3.1
%
204,144
3.0
%
188,237
3.1
%
Lease and rental expense
11,560
0.7
%
11,135
0.7
%
46,468
0.7
%
43,819
0.7
%
Subtotal-operating expenses
1,364,197
79.0
%
1,266,065
81.4
%
5,333,838
79.6
%
4,964,099
82.0
%
Income from operations
363,660
21.0
%
289,635
18.6
%
1,366,631
20.4
%
1,086,392
18.0
%
Interest expense, net
951
0.1
%
1,102
0.1
%
4,027
0.1
%
4,557
0.1
%
Other (income) expense, net
(1,139
)
(0.1
)%
(1,132
)
(0.1
)%
(3,480
)
(0.1
)%
(3,426
)
(0.1
)%
Income before income taxes
$
363,848
21.1
%
$
289,665
18.6
%
$
1,366,084
20.4
%
$
1,085,261
17.9
%
All Behavioral Health Care Services
Three months ended
Three months ended
Twelve months ended
Twelve months ended
December 31, 2024
December 31, 2023
December 31, 2024
December 31, 2023
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Amount
% of Net
Revenues
Net revenues
$
1,792,761
100.0
%
$
1,615,543
100.0
%
$
6,895,051
100.0
%
$
6,190,921
100.0
%
Operating charges:
Salaries, wages and benefits
913,005
50.9
%
854,670
52.9
%
3,603,123
52.3
%
3,353,008
54.2
%
Other operating expenses
393,496
21.9
%
353,353
21.9
%
1,447,503
21.0
%
1,303,311
21.1
%
Supplies expense
58,243
3.2
%
55,713
3.4
%
230,274
3.3
%
217,310
3.5
%
Depreciation and amortization
55,413
3.1
%
49,180
3.0
%
206,362
3.0
%
189,297
3.1
%
Lease and rental expense
11,751
0.7
%
11,194
0.7
%
46,986
0.7
%
44,028
0.7
%
Subtotal-operating expenses
1,431,908
79.9
%
1,324,110
82.0
%
5,534,248
80.3
%
5,106,954
82.5
%
Income from operations
360,853
20.1
%
291,433
18.0
%
1,360,803
19.7
%
1,083,967
17.5
%
Interest expense, net
951
0.1
%
1,102
0.1
%
4,027
0.1
%
4,558
0.1
%
Other (income) expense, net
(1,139
)
(0.1
)%
(1,132
)
(0.1
)%
(3,547
)
(0.1
)%
(4,271
)
(0.1
)%
Income before income taxes
$
361,041
20.1
%
$
291,463
18.0
%
$
1,360,323
19.7
%
$
1,083,680
17.5
%
We believe that providing our results on a “Same Facility” basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods.
Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2024.
The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months.
Universal Health Services, Inc.
Selected Hospital Statistics
For the Three Months Ended
December 31, 2024 and 2023
(unaudited)
AS REPORTED:
ACUTE
BEHAVIORAL HEALTH
12/31/24
12/31/23
% change
12/31/24
12/31/23
% change
Hospitals owned and leased
28
27
3.7
%
331
333
-0.6
%
Average licensed beds
6,707
6,674
0.5
%
24,220
24,285
-0.3
%
Average available beds
6,535
6,502
0.5
%
24,120
24,185
-0.3
%
Patient days
402,288
403,117
-0.2
%
1,588,205
1,575,040
0.8
%
Average daily census
4,372.7
4,381.7
-0.2
%
17,263.1
17,120.0
0.8
%
Occupancy-licensed beds
65.2
%
65.7
%
-0.7
%
71.3
%
70.5
%
1.1
%
Occupancy-available beds
66.9
%
67.4
%
-0.7
%
71.6
%
70.8
%
1.1
%
Admissions
84,245
82,918
1.6
%
115,435
113,604
1.6
%
Length of stay
4.8
4.9
-1.8
%
13.8
13.9
-0.8
%
Inpatient revenue
$
12,488,383
$
11,408,639
9.5
%
$
2,754,078
$
2,647,158
4.0
%
Outpatient revenue
8,645,327
7,566,625
14.3
%
285,076
275,128
3.6
%
Total patient revenue
21,133,710
18,975,264
11.4
%
3,039,154
2,922,286
4.0
%
Other revenue
251,226
234,117
7.3
%
83,795
83,153
0.8
%
Gross revenue
21,384,936
19,209,381
11.3
%
3,122,949
3,005,439
3.9
%
Total deductions
19,066,616
17,121,878
11.4
%
1,330,188
1,389,896
-4.3
%
Net revenue
$
2,318,320
$
2,087,503
11.1
%
$
1,792,761
$
1,615,543
11.0
%
SAME FACILITY:
ACUTE
BEHAVIORAL HEALTH
12/31/24
12/31/23
% change
12/31/24
12/31/23
% change
Hospitals owned and leased
27
27
0.0
%
330
330
0.0
%
Average licensed beds
6,657
6,674
-0.3
%
24,094
23,821
1.1
%
Average available beds
6,485
6,502
-0.3
%
23,994
23,721
1.2
%
Patient days
401,166
403,107
-0.5
%
1,578,242
1,550,485
1.8
%
Average daily census
4,360.5
4,381.6
-0.5
%
17,154.8
16,853.1
1.8
%
Occupancy-licensed beds
65.5
%
65.7
%
-0.2
%
71.2
%
70.7
%
0.6
%
Occupancy-available beds
67.2
%
67.4
%
-0.2
%
71.5
%
71.0
%
0.6
%
Admissions
83,943
82,918
1.2
%
114,684
112,232
2.2
%
Length of stay
4.8
4.9
-1.7
%
13.8
13.8
-0.4
%
Universal Health Services, Inc.
Selected Hospital Statistics
For the Twelve Months Ended
December 31, 2024 and 2023
AS REPORTED:
ACUTE
BEHAVIORAL HEALTH
12/31/24
12/31/23
% change
12/31/24
12/31/23
% change
Hospitals owned and leased
28
27
3.7
%
331
333
-0.6
%
Average licensed beds
6,670
6,691
-0.3
%
24,367
24,224
0.6
%
Average available beds
6,498
6,519
-0.3
%
24,280
24,124
0.6
%
Patient days
1,601,579
1,576,074
1.6
%
6,446,651
6,336,927
1.7
%
Average daily census
4,375.9
4,318.0
1.3
%
17,613.8
17,361.4
1.5
%
Occupancy-licensed beds
65.6
%
64.5
%
1.7
%
72.3
%
71.7
%
0.9
%
Occupancy-available beds
67.3
%
66.2
%
1.7
%
72.5
%
72.0
%
0.8
%
Admissions
331,415
322,218
2.9
%
476,584
472,307
0.9
%
Length of stay
4.8
4.9
-1.9
%
13.5
13.4
0.6
%
Inpatient revenue
$
50,010,778
$
44,687,035
11.9
%
$
11,129,548
$
10,648,996
4.5
%
Outpatient revenue
34,198,778
29,858,874
14.5
%
1,118,336
1,087,595
2.8
%
Total patient revenue
84,209,556
74,545,909
13.0
%
12,247,884
11,736,591
4.4
%
Other revenue
998,650
948,994
5.2
%
330,977
303,546
9.0
%
Gross revenue
85,208,206
75,494,903
12.9
%
12,578,861
12,040,137
4.5
%
Total deductions
76,285,879
67,413,501
13.2
%
5,683,810
5,849,216
-2.8
%
Net revenue
$
8,922,327
$
8,081,402
10.4
%
$
6,895,051
$
6,190,921
11.4
%
SAME FACILITY:
ACUTE
BEHAVIORAL HEALTH
12/31/24
12/31/23
% change
12/31/24
12/31/23
% change
Hospitals owned and leased
27
27
0.0
%
330
330
0.0
%
Average licensed beds
6,657
6,644
0.2
%
24,165
24,000
0.7
%
Average available beds
6,485
6,472
0.2
%
24,065
23,900
0.7
%
Patient days
1,600,445
1,569,792
2.0
%
6,397,790
6,277,015
1.9
%
Average daily census
4,372.8
4,300.8
1.7
%
17,480.3
17,197.3
1.6
%
Occupancy-licensed beds
65.7
%
64.7
%
1.5
%
72.3
%
71.7
%
1.0
%
Occupancy-available beds
67.4
%
66.5
%
1.5
%
72.6
%
72.0
%
0.9
%
Admissions
331,113
321,155
3.1
%
472,798
468,260
1.0
%
Length of stay
4.8
4.9
-2.0
%
13.5
13.4
0.7
%
Universal Health Services, Inc.
Supplemental Non-GAAP Disclosures
2025 Operating Results Forecast
(in thousands, except per share amounts)
Forecast For The Year Ending December 31, 2025
% Net
% Net
Low
revenues
High
revenues
Net revenues
$
17,020,000
$
17,364,000
G4Net income attributable to UHS (a)
$
1,199,798
$
1,297,005
Depreciation and amortization
639,574
639,574
Interest expense
150,253
150,253
Other (income) expense, net
(9,902
)
(9,902
)
Provision for income taxes
376,809
407,338
Adjusted EBITDA net of NCI (b)
$
2,356,532
13.8
%
$
2,484,268
14.3
%
Net income attributable to UHS, per diluted share (a)
$
18.45
$
19.95
Shares used in computing diluted earnings per share
65,017
65,017
(a) Forecasted net income attributable to UHS/per diluted share exclude the following items because we do not believe we can forecast these items with sufficient accuracy. Such items include: the impact of future items, if applicable, that are nonrecurring or non-operational in nature including items such as pre-tax unrealized gains/losses resulting from changes in the market value of shares of certain equity securities, the impact of ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m), and other potential material items including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, other amounts that may be reflected in the current or prior year financial statements that relate to prior periods, and the impact of share repurchases that differ from our forecasted assumptions.
Forecasted net income attributable to UHS/per diluted share is also subject to certain conditions including those as set forth in General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures.
(b) Adjusted EBITDA net of NCI is a non-GAAP financial measure and should not be considered a measure of financial performance under GAAP. We believe Adjusted EBITDA net of NCI is helpful to our investors as a measure of operating performance.
Mentions · how they’re counted
| Category | Underlined | Word counter | Model’s count |
|---|---|---|---|
| AI AI, artificial intelligence, generative AI, machine learning, large language model, LLM | 0 | — | — |
| Layoffs layoffs, RIF, headcount reduction, workforce optimization, restructuring | 0 | — | — |
| Recession recession, downturn, contraction, slowdown | 0 | — | — |
| Tariffs tariff, trade war, trade barriers, trade restrictions, trade policy | 0 | — | — |
| Buybacks share repurchase, buyback program | 2 | — | — |
Underlines use the same word lists the scores use. AI, recession and tariffs follow Palanor’s word counter, so those counts match it exactly on the same text. Layoffs and buybacks use the terms the model was given. The model’s count is an estimate by meaning, not by string, so it can differ from the underlines.
Source: SEC EDGAR · public domain · Highlights by Palanor